Pau Montesinos

Aug 23, 2024 | digitalcommons.library.tmc.edu | Jenny Byrne |Stephane de Botton |Pau Montesinos |Andre C Schuh

This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 (isocitrate dehydrogenase 2) inhibitor, with conventional care regimens (CCRs) in patients aged ≥60 years with late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R) to 2 or 3 prior AML-directed therapies.

Jun 26, 2023 | onclive.com | Pau Montesinos

Pau Montesinos, MD, PhD, attending physician, hematologist, University Hospital La Fe, Valencia, Spain, discusses preliminary efficacy seen with the addition of quizartinib to standard 7+3 chemotherapy in patients with newly diagnosed FLT3-ITD wild-type acute myeloid leukemia (AML). The phase 2 QUIWI trial (NCT04107727) was designed to compare event-free survival (EFS) outcomes with the combination vs placebo.